Patient benefit is used to assess the efficacy and feasibility of medical treatments. To assess patient benefit, a clear understanding of the patient's health prior to and after a procedure, treatment, or intervention is compared. Treatments which generate a patient benefit, with minimal or acceptable risks, may be approved for further clinical use.
Date: November 19, 2020 Time: 10:00am (PST), 1:00pm (EST) 98% of in-patients will undergo a diagnostic test during a hospital stay.[1] With the increased focus on the accuracy of diagnostic...
Date: November 17, 2020 Time: 5:00am (PST), 8:00am (EST), 2:00pm (CET) Septicemia is a serious clinical condition with roundabout 123,000 cases of sepsis a year in England. In recent years t...
Patient laboratory test results are significantly over-represented in electronic medical records, but significantly under-utilized in research. An important application of laboratory data is...
Date: November 10, 2020 Time: 5:00am (PST), 8:00am (EST), 2:00pm (CET) Dr. Stefan Zimmermann will talk about the use of Fourier Transform Infrared Spectroscopy for fast and reliable typing o...
DATE: November 4th, 2020 TIME: 11:00am PST As cell therapies become more complex, the need for robust analytical tools to characterize such products as they enter the clinic has increased in...
During the presentation, Dr. Hernandez-Losa will describe the experience in the Department of Pathology using NGS with S5-xl in different translational projects in solid tumors. Additionally...
During the presentation, Dr. Hernandez-Losa will describe the experience in the Department of Pathology using NGS with S5-xl in different translational projects in solid tumors. Additionally...
The treatment of cancer has remarkably improved because of increased knowledge of the molecular abnormalities that drive human cancer growth. This has led to the development of ever more eff...
The treatment of cancer has remarkably improved because of increased knowledge of the molecular abnormalities that drive human cancer growth. This has led to the development of ever more eff...
Date: September 16, 2020 Time: 7:00am (PDT), 10:00am (EDT) Of the 15 million patients admitted to US based hospitals with medical, non-surgical illnesses, 8 million possess inherent risk of...
Soluble cytokine biomarkers are the master regulators of cell-to-cell communication-- the means by which one cell tells another what to do or where to go. Determining the biomarker signature...
DATE: October 8, 2020 TIME: 1:00pm PDT Microsatellite instability (MSI) has evolved as a marker of potential hereditary cancer risk and is now a tissue agnostic immune biomarker with a broad...
Mutations in the epidermal growth factor receptor gene (EGFR) and the known Kirsten rat sarcoma viral oncogene (KRAS) are significant drivers in the development of non-small-cell lung cancer...
Every patient is different and so is every tumor! The term “personalized oncology” today is largely associated with sequencing approaches. Current publications proof more and mor...
Immune therapy approaches are being used in many different solid cancers today including clear cell renal carcinoma (mccRCC) and metastatic prostate adenocarcinoma. Over the past few years i...
Laws enforcing the prohibition of cannabis have unjustly harmed people of color for nearly a century. As a result, the regulated cannabis industry has a duty to advocate for legalization tha...
Come join us for a live chat with Bernd Bodenmiller. When you enter the meeting room you can raise your hand to be unmuted by our moderator to ask your questions or just introduce yourself a...
Single-cell mass cytometry identifies mechanisms of resistance to immunotherapy in AML 6:30–7:00 am PDT Presented By: Shelley Herbrich, PhD Understanding CD19 negative relapse followin...
Chronic kidney disease (CKD) is a major public health threat, affecting 11-15% of the U.S. population alone. Currently, there are no effective therapies to cure CKD. Drug therapies are not p...
This presentation will discuss the use of the FDA EUA process to implement SARS-CoV-2 assays to address the COVID-19 pandemic. The use of a team-based approach, through an Incident Command s...
Advances in genomics and molecular biomarker testing have led to tremendous improvements, ushering in a new era of personalized medicine especially in the oncology practice. Many of these bi...
July 29, 2020 TIME: 9:00am PDT, 12:009m EDT, 6:00pm CEST Hepatitis C infection, once a formidable enemy, is now a curable disease. Dramatic advances in antiviral therapies have launched a ne...
Cytokine storm is suspected of producing the overzealous immune response driving the severe cardiopulmonary complications that fuel high morbidity and mortality rates in certain COVID-19 inf...
DATE: July 07, 2020 TIME: 9:00 am PDT The widely used TNM staging system is poorly predictive of response to adjuvant chemotherapy in Stage II and III colon cancer. As a result, there is ove...
Date: November 19, 2020 Time: 10:00am (PST), 1:00pm (EST) 98% of in-patients will undergo a diagnostic test during a hospital stay.[1] With the increased focus on the accuracy of diagnostic...
Date: November 17, 2020 Time: 5:00am (PST), 8:00am (EST), 2:00pm (CET) Septicemia is a serious clinical condition with roundabout 123,000 cases of sepsis a year in England. In recent years t...
Patient laboratory test results are significantly over-represented in electronic medical records, but significantly under-utilized in research. An important application of laboratory data is...
Date: November 10, 2020 Time: 5:00am (PST), 8:00am (EST), 2:00pm (CET) Dr. Stefan Zimmermann will talk about the use of Fourier Transform Infrared Spectroscopy for fast and reliable typing o...
DATE: November 4th, 2020 TIME: 11:00am PST As cell therapies become more complex, the need for robust analytical tools to characterize such products as they enter the clinic has increased in...
During the presentation, Dr. Hernandez-Losa will describe the experience in the Department of Pathology using NGS with S5-xl in different translational projects in solid tumors. Additionally...
During the presentation, Dr. Hernandez-Losa will describe the experience in the Department of Pathology using NGS with S5-xl in different translational projects in solid tumors. Additionally...
The treatment of cancer has remarkably improved because of increased knowledge of the molecular abnormalities that drive human cancer growth. This has led to the development of ever more eff...
The treatment of cancer has remarkably improved because of increased knowledge of the molecular abnormalities that drive human cancer growth. This has led to the development of ever more eff...
Date: September 16, 2020 Time: 7:00am (PDT), 10:00am (EDT) Of the 15 million patients admitted to US based hospitals with medical, non-surgical illnesses, 8 million possess inherent risk of...
Soluble cytokine biomarkers are the master regulators of cell-to-cell communication-- the means by which one cell tells another what to do or where to go. Determining the biomarker signature...
DATE: October 8, 2020 TIME: 1:00pm PDT Microsatellite instability (MSI) has evolved as a marker of potential hereditary cancer risk and is now a tissue agnostic immune biomarker with a broad...
Mutations in the epidermal growth factor receptor gene (EGFR) and the known Kirsten rat sarcoma viral oncogene (KRAS) are significant drivers in the development of non-small-cell lung cancer...
Every patient is different and so is every tumor! The term “personalized oncology” today is largely associated with sequencing approaches. Current publications proof more and mor...
Immune therapy approaches are being used in many different solid cancers today including clear cell renal carcinoma (mccRCC) and metastatic prostate adenocarcinoma. Over the past few years i...
Laws enforcing the prohibition of cannabis have unjustly harmed people of color for nearly a century. As a result, the regulated cannabis industry has a duty to advocate for legalization tha...
Come join us for a live chat with Bernd Bodenmiller. When you enter the meeting room you can raise your hand to be unmuted by our moderator to ask your questions or just introduce yourself a...
Single-cell mass cytometry identifies mechanisms of resistance to immunotherapy in AML 6:30–7:00 am PDT Presented By: Shelley Herbrich, PhD Understanding CD19 negative relapse followin...
Chronic kidney disease (CKD) is a major public health threat, affecting 11-15% of the U.S. population alone. Currently, there are no effective therapies to cure CKD. Drug therapies are not p...
This presentation will discuss the use of the FDA EUA process to implement SARS-CoV-2 assays to address the COVID-19 pandemic. The use of a team-based approach, through an Incident Command s...
Advances in genomics and molecular biomarker testing have led to tremendous improvements, ushering in a new era of personalized medicine especially in the oncology practice. Many of these bi...
July 29, 2020 TIME: 9:00am PDT, 12:009m EDT, 6:00pm CEST Hepatitis C infection, once a formidable enemy, is now a curable disease. Dramatic advances in antiviral therapies have launched a ne...
Cytokine storm is suspected of producing the overzealous immune response driving the severe cardiopulmonary complications that fuel high morbidity and mortality rates in certain COVID-19 inf...
DATE: July 07, 2020 TIME: 9:00 am PDT The widely used TNM staging system is poorly predictive of response to adjuvant chemotherapy in Stage II and III colon cancer. As a result, there is ove...
Opens in a new windowOpens an external siteOpens an external site in a new window
Follow
